Lorlatinib/lorlatinib (Borina) main functions and indications

Lorlatinib/ Lorlatinib ( Lorlatinib) is a targeted drug targeting ALK (anaplastic lymphoma kinase) and ROS1 gene mutations. Its main function is to inhibit tumor growth by inhibiting the proliferation of cancer cells caused by mutations in these genes. Lorlatinib, as an ALK inhibitor, is specifically targeted at patients with non-small cell lung cancer (NSCLC) who have developed resistance to other ALK inhibitors. It can inhibit abnormal cell signaling caused by ALK mutations, thereby effectively preventing the proliferation of tumor cells and slowing down the progression of the disease.

The main indications for lorlatinib are patients with ALK-positive non-small cell lung cancer (NSCLC), especially those who have received other ALK-targeted therapies and developed resistance. Studies have shown that lorlatinib can significantly improve the progression-free survival (PFS) of these patients and improve their quality of life. In addition to ALK mutations, lorlatinib has also shown efficacy against ROS1 gene mutations in clinical trials, which makes it not only suitable for ALK-positive lung cancer patients, but also provides a new treatment option for ROS1-positive patients.

The role of lorlatinib is not limited to lung cancer. In recent years, the scope of indications for lorlatinib has been continuously expanded, especially in tumor types that are resistant to other targeted therapies. Lorlatinib also shows certain therapeutic potential. Lorlatinib can effectively overcome the resistance that emerged in previous treatments and provide patients with new survival opportunities. Therefore, its role in cancer treatment is receiving increasing attention and may be used to treat other genetic mutation-related cancers in the future.

In general, the main function of lorlatinib is to inhibit cancer cell proliferation by targeting ALK and ROS1 gene mutations, and is especially suitable for patients with non-small cell lung cancer who are resistant to other ALK inhibitors.

References：https://www.lorbrena.com/